Latex agglutination assay

• US 5,231,035 A
• Filed: 01/11/1991
• Issued: 07/27/1993
• Est. Priority Date: 01/11/1991
• Status: Expired due to Term

• Current Assignee: Wilian Holding Company
• Original Assignee: Akers Research Corporation
• Inventors: Akers, Raymond F. Jr.
• Primary Examiner(s): Saunders, David
• Assistant Examiner(s): Chin, Christopher L.
• Application Number:
  US07/640,037
• Time in Patent Office: 928 Days
• Field of Search: 436/518, 436/523, 436/524, 436/527, 436/528, 436/529, 436/531, 436/534, 436/805, 436/815-818, 436/536, 436/538, 436/541
• US Class Current: 436/531
• CPC Class Codes: G01N 33/54313 the carrier being characterised by its particulate form
• CPC Class Codes: G01N 33/585 with a particulate label, e.g. coloured latex
• CPC Class Codes: Y10S 436/805 Optical property
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds
• CPC Class Codes: Y10S 436/816 Alkaloids, amphetamines, and barbiturates
• CPC Class Codes: Y10S 436/817 Steroids or hormones
• CPC Class Codes: Y10S 436/818 Human chorionic gonadotropin

Abstract

Methods for determining the presence of a first ligand, preferably a hapten, in a sample suspected to contain the first ligand are provided, along with reagent systems and apparatus suitable for performing the methods. The methods depend upon a color visualization indicating the presence or absence of the first ligand in the sample. Preferred methods comprise contacting the sample with a reagent system which comprises: (1) colored particles which bear on their surface a second ligand which may be the same as or different than the first ligand; and (2) an amount of a receptor which is specific for the first ligand and the second ligand, wherein the amount is sufficient to stabilize the particles. The methods further comprise passing the contacted sample and reagent system through a filter, and then analyzing the color of the filtrate. The presence of ligand in the sample is established where the color of the filtrate is substantially different from the color of the ligand-bearing particles.

Claims

1. A method for determining the presence of a first ligand in a sample suspected to contain the first ligand, comprising:

providing a reagent system which comprises;

a plurality of particles which have the capacity to form multiple-particle aggregates and which bear on their surface a second ligand which is the same as or different than the first ligand; and

an amount of a receptor which is specific for the first ligand and the second ligand, wherein the amount of receptor is sufficient to prevent formation of multiple-particle aggregates in the absence of the first ligand;

forming a test mixture by contacting the reagent system with the sample;

passing the test mixture through a filter having apertures which are larger than the particles but smaller than the aggregates, thereby producing a filtrate; and

analyzing the filtrate to determine the presence of the particles, the presence of particles in the filtrate indicating the absence of the first ligand in the sample and the absence of particles in the filtrate indicating the presence of the first ligand in the sample.

2. The method of claim 1 wherein the first ligand and the second ligand each have one active site.

3. The method of claim 1 wherein the first ligand and the second ligand are each haptens.

4. The method of claim 1 wherein the receptor is an antibody to a hapten.

5. The method of claim 1 wherein the first ligand and the second ligand are each antigens.

6. The method of claim 1 wherein the receptor is an antibody to an antigen.

7. The method of claim 1 wherein the first ligand and the second ligand are independently selected from the group consisting of tetrahydrocannabinol and its metabolites, cocaine and its metabolites, morphine and other opiates, amphetamine, phencyclidine, barbiturates, steroids, human chorionic gonadotropin, luteinizing hormone, and theophylline.

8. The method of claim 1 wherein the sample comprises a mammalian bodily fluid.

9. The method of claim 1 wherein the particles have a mean diameter of from about 0.01 micrometers to about 10 micrometers.

10. The method of claim 1 wherein the particles have a mean diameter of about 0.3 micrometers.

11. The method of claim 1 wherein the particles comprise latex.

12. The method of claim 1 wherein the particles comprise polystyrene or styrene primary amino latex.

13. The method of claim 1 wherein the particles have a visually recognizable color.

14. The method of claim 1 wherein the contacting step is performed for a length of time sufficient to form multiple-particle aggregates.

15. The method of claim 1 wherein the contacting step is performed by contacting the sample with a solution which comprises particles and a solution which comprises the receptor.

16. The method of claim 1 wherein the contacting step is performed in a reaction cell.

17. The method of claim 1 wherein the contacting step is performed by contacting the sample with a substrate which comprises the reagent system.

18. The method of claim 1 wherein the filter comprises a controlled pore membrane.

19. The method of claim 1 wherein the filter comprises polycarbonate.

20. The method of claim 1 wherein the apertures are from about 5 to about 15 times larger than the particles.

21. The method of claim 1 wherein the apertures are from about 10 to about 12 times larger than the particles.

22. The method of claim 1 wherein the apertures are about 3 micrometers in diameter.

23. The method of claim 1 wherein the filtrate has a visually recognizable color.

24. The method of claim 1 wherein the analyzing step comprises visually determining the color of the filtrate.

25. The method of claim 1 wherein the analyzing step comprises comparing the appearance of the filtrate with a visual standard corresponding to a known concentration of the particles.

26. The method of claim 1 further comprising contacting the filtrate with a solution effective for inactivating biological moieties present in the filtrate.